©The Author(s) 2024.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 61-78
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.61
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.61
Table 1 The correlations between the C-reactive protein to albumin ratio and clinicopathological factors, n (%)
| CAR ≤ 1.20 (n = 94) | CAR > 1.20 (n = 66) | Total (n = 160) | P value | |
| Age (yr) | 0.143 | |||
| ≤ 60 | 75 (79.8) | 46 (69.7) | 121 (75.6) | |
| > 60 | 19 (20.2) | 20 (30.3) | 39 (24.4) | |
| Gender | 0.045 | |||
| Male | 77 (81.9) | 57 (86.4) | 134 (83.8) | |
| Female | 17 (18.1) | 9 (13.6) | 26 (16.3) | |
| Hepatitis infection | 0.988 | |||
| No | 17 (18.1) | 12 (18.2) | 29 (18.1) | |
| Yes | 77 (81.9) | 54 (81.8) | 131 (81.9) | |
| Child-Pugh grade | 0.749 | |||
| A | 75 (79.8) | 54 (81.8) | 129 (80.6) | |
| B | 19 (21.2) | 12 (18.2) | 31 (19.4) | |
| AFP level (ng/L) | 0.365 | |||
| ≤ 400 | 58 (61.7) | 36 (54.5) | 94 (58.8) | |
| > 400 | 36 (38.3) | 30 (45.5) | 66 (41.3) | |
| ECOG PS | 0.990 | |||
| 0 | 30 (31.9) | 21 (31.8) | 51 (31.9) | |
| ≥ 1 | 64 (68.1) | 45 (68.2) | 109 (68.1) | |
| Tumor size (cm) | 0.248 | |||
| ≤ 5 | 26 (27.7) | 13 (19.7) | 39 (24.4) | |
| > 5 | 68 (72.3) | 53 (80.3) | 121 (75.6) | |
| Tumor number | 0.512 | |||
| Single | 18 (19.1) | 10 (15.2) | 28 (17.5) | |
| Multiple | 76 (80.9) | 56 (84.8) | 132 (82.5) | |
| Macroscopic vascular invasion | 0.013 | |||
| Absent | 60 (63.8) | 29 (43.9) | 89 (55.6) | |
| Present | 34 (36.2) | 37 (56.1) | 71 (44.4) | |
| Extrahepatic metastasis | 0.173 | |||
| Absent | 41 (43.6) | 36 (54.5) | 77 (48.1) | |
| Present | 53 (56.4) | 30 (45.5) | 83 (51.9) | |
| Diabetes | 0.955 | |||
| No | 84 (89.4) | 59 (89.4) | 143 (89.4) | |
| Yes | 10 (10.6) | 7 (10.6) | 17 (10.6) | |
| Hypertension | 0.455 | |||
| No | 81 (86.2) | 54 (81.8) | 135 (84.4) | |
| Yes | 13 (13.8) | 12 (18.2) | 25 (15.6) | |
| Smoke | 0.013 | |||
| No | 60 (63.8) | 29 (43.9) | 89 (55.6) | |
| Yes | 34 (36.2) | 37 (56.1) | 71 (44.4) | |
| Drink | 0.364 | |||
| No | 51 (54.3) | 31 (47.0) | 82 (51.2) | |
| Yes | 43 (45.7) | 35 (53.0) | 78 (48.8) | |
| Cirrhosis | 0.191 | |||
| No | 40 (42.6) | 35 (53.0) | 75 (46.9) | |
| Yes | 54 (57.4) | 31 (47.0) | 85 (53.1) | |
| Previous Ablation | 0.119 | |||
| No | 87 (92.6) | 56 (84.8) | 143 (89.4) | |
| Yes | 7 (7.4) | 10 (15.2) | 17 (10.6) | |
| Previous TACE | 0.505 | |||
| No | 52 (55.3) | 40 (60.6) | 92 (57.) | |
| Yes | 42 (44.7) | 26 (39.4) | 68 (42.5) | |
| Previous Surgery | 0.701 | |||
| No | 57 (60.6) | 42 (63.6) | 99 (61.9) | |
| Yes | 37 (39.4) | 24 (36.4) | 61 (38.1) | |
| BCLC stage | 0.966 | |||
| A | 6 (6.4) | 4 (6.1) | 10 (6.3) | |
| B | 17 (18.1) | 13 (19.7) | 30 (18.8) | |
| C | 71 (75.5) | 49 (74.2) | 120 (75.0) |
- Citation: Li BB, Chen LJ, Lu SL, Lei B, Yu GL, Yu SP. C-reactive protein to albumin ratio predict responses to programmed cell death-1 inhibitors in hepatocellular carcinoma patients. World J Gastrointest Oncol 2024; 16(1): 61-78
- URL: https://www.wjgnet.com/1948-5204/full/v16/i1/61.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i1.61